Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
Ji-Yeon KimEunjin LeeKyunghee ParkSeock-Ah ImJoohyuk SohnKeun Seok LeeYee Soo ChaeJee Hyun KimTae-Yong KimKyung Hae JungYeon Hee Parknull nullPublished in: Breast cancer research and treatment (2019)
ClinicalTrials.gov number: NCT02263495.